Capstone Investment Advisors
TGTX icon

Capstone Investment Advisors’s TG Therapeutics TGTX Stock Holding History

Capstone Investment Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$693K Buy
+12,611
New +$516K ﹤0.01% 1090
2025
Q4 		– Sell
-13,020
Closed -$470K – 2044
2025
Q3 		$470K Buy
+13,020
New +$429K ﹤0.01% 1415

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Capstone Investment Advisors's TGTX Position: Q2 2026 in Review

Capstone Investment Advisors opened a new position in TG Therapeutics (TGTX) in Q2 2026: 12,611 shares worth $693K. The stake represents ﹤0.01% of the portfolio and ranks #1090 among its holdings. This is a return to the name: Capstone Investment Advisors previously reported a position in TGTX as recently as Q3 2025.

Capstone Investment Advisors first reported a position in TGTX in Q3 2025 and has held it in 2 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Capstone Investment Advisors held 12,611 shares of TG Therapeutics worth $693K as of Q2 2026.
  • TG Therapeutics was a new Capstone Investment Advisors position in Q2 2026.
  • TG Therapeutics made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q2 2026, its #1090 holding.
  • Capstone Investment Advisors first reported a position in TG Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.